All study medication was discontinued at discharge.COVID subjects in Taleghani hospital are managed by six different specialists in infectious disease. Search for other works by this author on: Typically used in combination with ribavirin, interferons have been studied for patients with other coronaviruses, with mixed results. The critical need for treatment and patient care in outbreak settings, on the frontlines of nCoV outbreaks, will place stress on any medical system and clinical research mechanism. All authors were involved in critical revision of the manuscript and final approval of the published version.Oxford University Press is a department of the University of Oxford. For permissions, please email: [email protected].
2019 Apr;32(2):137-144. There was no report of COVID-related complications or re-admission.In this open-label trial, the effects of sofosbuvir/daclatasvir and ribavirin in patients with severe COVID-19 were measured. On the other hand, there are challenges of conducting controlled clinical studies in an outbreak environment, the limitations of retrospective studies, and the absence of nCoV cases showing acute resolution of infection after treatment as well as in vitro testing data of activity against 2019‐nCoV.The pathology of COVID‐19 resembles that of the 2013 MERS‐CoV and 2003 SARS‐CoV infections such that the extrapolation of treatment guidance from those prior clinical experiences can provide guidance for the current outbreak of 2019‐nCoV.As strain isolates of the 2019‐nCoV are distributed for laboratory testing in cell‐based and animal model systems, recommendations for treatment may be ascribed. However, controlled clinical studies are underway to permit a prospective evaluation of efficacy, and the government Treatment Plan Edition 5 and revised and prescribed usage guidelines distributed in China will assist in the comparability of multicenter experiences in retrospective analyses.
With the national standard COVID-19 treatment protocol at the time being lopinavir/ritonavir 200/50 mg two tablets every 12 h plus hydroxychloroquine 400 mg daily, it was decided to conduct a two-arm trial where both arms would receive the standard protocol in addition to either ribavirin or sofosbuvir/daclatasvir. Infectious and Tropical Diseases Research Centre, Ahwaz Jundishapur University of Medical Sciences Search for other works by this author on: Treating COVID-19—off-label drug use, compassionate use, and randomized clinical trials during pandemicsRemdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19Structure of the RNA-dependent RNA polymerase from COVID-19 virusStructure of M(pro) from SARS-CoV-2 and discovery of its inhibitorsSofosbuvir, galidesivir, and tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking studyNucleotide analogues as inhibitors of SARS-CoV polymeraseNucleotide analogues as inhibitors of SARS-CoV-2 polymerasePrediction of small molecule inhibitors targeting the novel coronavirus (SARS-CoV-2) RNA-dependent RNA polymerasePredicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning modelIn silico study of various antiviral drugs, vitamins, and natural substances as potential binding compounds with SARS-CoV-2 main proteaseThe in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndromeSD1000: high sustained viral response rate in 1361 patients with hepatitis C genotypes 1, 2, 3, and 4 using a low-cost, fixed-dose combination tablet of generic sofosbuvir and daclatasvir: a multicenter, phase III clinical trialThe combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairmentA trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19Remdesivir for the treatment of COVID-19—preliminary reportRemdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialFavipiravir versus arbidol for COVID-19: a randomized clinical trial© The Author(s) 2020.
Department of Epidemiology, Tehran University of Medical Sciences The dosage regimen was 30 mg/kg IV as a loading dose, then 16 mg/kg IV every 6 hours for 4 days, followed by 8 mg/kg IV every 8 hours for 3 days.